leadf
logo-loader
viewIXICO PLC

IXICO rises amid tie-up with ‘leading' pharma'

It is expected to make a material contribution to IXICO’s revenue in the next 12-18 months

nurse-computer.jpg
A digital healthcare platform will help monitor and manage treatment for multiple sclerosis

IXICO (LON:IXI) advanced in early deals after revealing a strategic collaboration with an un-named leading pharmaceutical company and independent expert clinical centres.

The collaboration is expected to see IXICO develop an adapted version of its digital healthcare platform to help monitor and manage approved pharmaceutical treatments for multiple sclerosis in the EU and Canada.

It is expected to start this month, and the anticipated table sees the platform in a clinical setting in 2016.

Chief executive Professor Derek Hill expects the collaboration to make a material contribution to IXICO’s revenue in the next 12-18 months, which he says underpins the group’s confidence in meeting market expectations.

John Hall, IXICO senior vice president of commercial operations, meanwhile, said: “We are delighted that this new collaboration will expand the use of our Assessa platform into another clinical area alongside currently approved treatments, further extending the reach and application of our technology and expertise.”

In early deals, IXICO shares gained up to 8% to trade at 33p each.

Quick facts: IXICO PLC

Price: 103.1 GBX

AIM:IXI
Market: AIM
Market Cap: £48.55 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of IXICO PLC named herein, including the promotion by the Company of IXICO PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Market report: UK approves Pfizer/BioNTech vaccine and lockdown ends

FTSE 100 consolidated after its recent surge even though there was more positive vaccine news and England’s lockdown ended. London’s blue-chip index was flat at 6,385 in early trading.   The UK has become the first country to approve the coronavirus vaccine developed by Pfizer Inc....

2 days, 1 hour ago

2 min read